Biomarkers of treatment response in multiple sclerosis

References

• Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010;74(24):2004-15
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47(6):707-17
   PubMed Web of Science ®Google Scholar
• Hemmer B, Hartung HP. Toward the development of rational therapies in multiple sclerosis: what is on the horizon? Ann Neurol 2007;62(4):314-26
   PubMed Web of Science ®Google Scholar
• Buck D, Hemmer B. Treatment of multiple sclerosis: current concepts and future perspectives. J Neurol 2011;258(10):1747-62
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006;253(1):98-108
   PubMed Web of Science ®Google Scholar
• Bates D. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials. Neurology 2011;76(1 Suppl 1):S14-25
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69(2):292-302
   PubMed Web of Science ®Google Scholar
• Rocca MA, Messina R, Filippi M. Multiple sclerosis imaging: recent advances. J Neurol 2013;260(3):929-35
   PubMed Web of Science ®Google Scholar
• Henderson AP, Altmann DR, Trip AS, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain 2010;133(9):2592-602
   PubMedGoogle Scholar
• Costello F, Hodge W, Pan YI, et al. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mult Scler 2008;14(7):893-905
   PubMed Web of Science ®Google Scholar
• Pulicken M, Gordon-Lipkin E, Balcer LJ, et al. Optical coherence tomography and disease subtype in multiple sclerosis. Neurology 2007;69(22):2085-92
   PubMed Web of Science ®Google Scholar
• Petzold A, De Boer JF, Schippling S, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 2010;9(9):921-32
   PubMed Web of Science ®Google Scholar
• Zimmermann H, Freing A, Kaufhold F, et al. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler 2013;19(4):443-50
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci 2008;29(Suppl 2):S211-13
   PubMed Web of Science ®Google Scholar
• Bielekova B, Martin R. Development of biomarkers in multiple sclerosis. Brain 2004;127(Pt 7):1463-78
   PubMedGoogle Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-52
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005;23:683-747
   PubMed Web of Science ®Google Scholar
• Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet 2008;9(7):516-26
   PubMed Web of Science ®Google Scholar
• Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-62
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Tumani H, Bennett JL, et al. Consensus guidelines for CSF and blood biobanking for CNS biomarker studies. Mult Scler Int 2011;2011:246412
   PubMedGoogle Scholar
• Kabat EA, Moore DH, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and their relationship to the serum proteins. J Clin Invest 1942;21(5):571-7
   PubMedGoogle Scholar
• Joseph FG, Hirst CL, Pickersgill TP, et al. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009;80(3):292-6
   PubMed Web of Science ®Google Scholar
• Cepok S, Jacobsen M, Schock S, et al. Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis. Brain 2001;124(Pt 11):2169-76
   PubMed Web of Science ®Google Scholar
• Kuenz B, Lutterotti A, Ehling R, et al. Cerebrospinal fluid B cells correlate with early brain inflammation in multiple sclerosis. PLoS ONE 2008;3(7):e2559
   Web of Science ®Google Scholar
• Tintore M, Rovira A, Rio J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70(13 Pt 2):1079-83
   PubMed Web of Science ®Google Scholar
• Zipoli V, Hakiki B, Portaccio E, et al. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Mult Scler 2009;15(4):472-8
   PubMed Web of Science ®Google Scholar
• Piccio L, Naismith RT, Trinkaus K, et al. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010;67(6):707-14
   PubMed Web of Science ®Google Scholar
• Saiz A, Carreras E, Berenguer J, et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Neurology 2001;56(8):1084-9
   PubMed Web of Science ®Google Scholar
• Walsh MJ, Tourtellotte WW. Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 1986;163(1):41-53
   PubMed Web of Science ®Google Scholar
• Jarius S, Franciotta D, Bergamaschi R, et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2008;79(10):1134-6
   PubMed Web of Science ®Google Scholar
• Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler 1998;4(3):111-17
   PubMed Web of Science ®Google Scholar
• Jarius S, Eichhorn P, Jacobi C, et al. The intrathecal, polyspecific antiviral immune response: specific for MS or a general marker of CNS autoimmunity? J Neurol Sci 2009;280(1-2):98-100
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Tumani H, Kiechle U, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS ONE 2009;4(11):e7638
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-7
   PubMed Web of Science ®Google Scholar
• Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66(5):617-29
   PubMed Web of Science ®Google Scholar
• Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66(5):630-43
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66(10):1485-9
   PubMed Web of Science ®Google Scholar
• Jarius S, Aboul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131(Pt 11):3072-80
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76(15):1310-15
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Saadoun S, et al. Anti-Aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71(3):314-22
   PubMed Web of Science ®Google Scholar
• Berger T, Rubner P, Schautzer F, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349(2):139-45
   PubMed Web of Science ®Google Scholar
• Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009;66(6):833-42
   PubMed Web of Science ®Google Scholar
• Wang H, Munger KL, Reindl M, et al. Myelin oligodendrocyte glycoprotein antibodies and multiple sclerosis in healthy young adults. Neurology 2008;71(15):1142-6
   PubMed Web of Science ®Google Scholar
• Mclaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009;183(6):4067-76
   PubMed Web of Science ®Google Scholar
• Lalive PH, Hausler MG, Maurey H, et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult Scler 2011;17(3):297-302
   PubMed Web of Science ®Google Scholar
• Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011;77(6):580-8
   PubMed Web of Science ®Google Scholar
• Lolli F, Mulinacci B, Carotenuto A, et al. An N-glucosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. Proc Natl Acad Sci USA 2005;102(29):10273-8
   PubMed Web of Science ®Google Scholar
• Lolli F, Mazzanti B, Pazzagli M, et al. The glycopeptide CSF114(Glc) detects serum antibodies in multiple sclerosis. J Neuroimmunol 2005;167(1-2):131-7
   PubMed Web of Science ®Google Scholar
• Schwarz M, Spector L, Gortler M, et al. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci 2006;244(1-2):59-68
   PubMed Web of Science ®Google Scholar
• Brettschneider J, Jaskowski TD, Tumani H, et al. Serum anti-GAGA4 IgM antibodies differentiate relapsing remitting and secondary progressive multiple sclerosis from primary progressive multiple sclerosis and other neurological diseases. J Neuroimmunol 2009;217(1-2):95-101
   PubMed Web of Science ®Google Scholar
• Querol L, Clark PL, Bailey MA, et al. Protein array-based profiling of CSF identifies RBPJ as an autoantigen in multiple sclerosis. Neurology 2013;81(11):956-63
   PubMed Web of Science ®Google Scholar
• Pandey S, Dioni I, Lambardi D, et al. Alpha actinin is specifically recognized by Multiple Sclerosis autoantibodies isolated using an N-glucosylated peptide epitope. Mol Cell Proteomics 2013;12(2):277-82
   PubMed Web of Science ®Google Scholar
• Mathey EK, Derfuss T, Storch MK, et al. Neurofascin as a novel target for autoantibody-mediated axonal injury. J Exp Med 2007;204(10):2363-72
   PubMed Web of Science ®Google Scholar
• Derfuss T, Parikh K, Velhin S, et al. Contactin-2/TAG-1-directed autoimmunity is identified in multiple sclerosis patients and mediates gray matter pathology in animals. Proc Natl Acad Sci USA 2009;106(20):8302-7
   PubMed Web of Science ®Google Scholar
• Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367(2):115-23
   PubMed Web of Science ®Google Scholar
• Higashi K, Fujita A, Inanobe A, et al. An inwardly rectifying K(+) channel, Kir4.1, expressed in astrocytes surrounds synapses and blood vessels in brain. Am J Physiol Cell Physiol 2001;281(3):C922-31
   Web of Science ®Google Scholar
• Elliott C, Lindner M, Arthur A, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012;135(Pt 6):1819-33
   PubMedGoogle Scholar
• Ayoglu B, Haggmark A, Khademi M, et al. Autoantibody profiling in multiple sclerosis using arrays of human protein fragments. Mol Cell Proteomics 2013;12(9):2657-72
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Farez MF, Izquierdo G, et al. Antigen microarrays identify CNS-produced autoantibodies in RRMS. Neurology 2012;78(8):532-9
   PubMed Web of Science ®Google Scholar
• Cohen BA, Oger J, Gagnon A, Giovannoni G. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008;275(1-2):7-17
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;69(14):1391-403
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Koch-Henriksen N, Ross C, et al. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005;65(1):33-9
   PubMed Web of Science ®Google Scholar
• Gneiss C, Reindl M, Berger T, et al. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 2004;24(5):283-90
   PubMed Web of Science ®Google Scholar
• Pachner AR, Warth JD, Pace A, Goelz S. Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study. Neurology 2009;73(18):1493-500
   PubMed Web of Science ®Google Scholar
• Van Der Voort LF, Visser A, Knol DL, et al. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis. Eur J Neurol 2009;16(9):1049-52
   PubMed Web of Science ®Google Scholar
• Pachner AR, Cadavid D, Wolansky L, Skurnick J. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009;73(18):1485-92
   PubMed Web of Science ®Google Scholar
• Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996;47(4):889-94
   PubMed Web of Science ®Google Scholar
• Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362(9391):1184-91
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Hurwitz B, et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007;68(13):977-84
   PubMed Web of Science ®Google Scholar
• Hemmer B, Stuve O, Kieseier B, et al. Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis. Lancet Neurol 2005;4(7):403-12
   PubMed Web of Science ®Google Scholar
• Hoffmann S, Cepok S, Grummel V, et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008;83(2):219-27
   PubMed Web of Science ®Google Scholar
• Buck D, Cepok S, Hoffmann S, et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011;68(4):480-7
   PubMedGoogle Scholar
• Weber F, Cepok S, Wolf C, et al. Single-nucleotide polymorphisms in HLA- and non-HLA genes associated with the development of antibodies to interferon-beta therapy in multiple sclerosis patients. Pharmacogenomics J 2012;12(3):238-45
   PubMed Web of Science ®Google Scholar
• Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361(11):1067-74
   PubMed Web of Science ®Google Scholar
• Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010;9(3):264-72
   PubMed Web of Science ®Google Scholar
• Rudick RA, O'connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010;68(3):304-10
   PubMed Web of Science ®Google Scholar
• Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 2010;68(3):295-303
   PubMed Web of Science ®Google Scholar
• Plavina T, Subramanyam M, Bloomgren G, et al. Use of JC virus antibody index to stratify risk of progressive mutlifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis. Abstract ENS Congress 2013; 29 May – 1 June 2013, Orlando, FL, USA
   Google Scholar
• Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology 2013;81(10):865-71
   PubMed Web of Science ®Google Scholar
• Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011;476(7359):214-19
   PubMed Web of Science ®Google Scholar
• Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet 2013;45:1353-60
   PubMed Web of Science ®Google Scholar
• De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009;8(12):1111-19
   PubMed Web of Science ®Google Scholar
• Pappas DJ, Oksenberg JR. Multiple sclerosis pharmacogenomics: maximizing efficacy of therapy. Neurology 2010;74(Suppl 1):S62-9
   PubMed Web of Science ®Google Scholar
• Tumani H, Hartung HP, Hemmer B, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis 2009;35(2):117-27
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Nath A. After the storm: neurofilament levels as a surrogate endpoint for neuroaxonal damage. Neurology 2011;76(14):1200-1
   PubMed Web of Science ®Google Scholar
• Teunissen CE, Iacobaeus E, Khademi M, et al. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Neurology 2009;72(15):1322-9
   PubMed Web of Science ®Google Scholar
• Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011;76(14):1206-13
   PubMed Web of Science ®Google Scholar
• Kuhle J, Malmestrom C, Axelsson M, et al. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013;128(6):e33-6
   PubMed Web of Science ®Google Scholar
• Ehling R, Lutterotti A, Wanschitz J, et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler 2004;10(6):601-6
   PubMed Web of Science ®Google Scholar
• Silber E, Semra YK, Gregson NA, Sharief MK. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology 2002;58(9):1372-81
   PubMed Web of Science ®Google Scholar
• Comabella M, Fernandez M, Martin R, et al. Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 2010;133(Pt 4):1082-93
   PubMed Web of Science ®Google Scholar
• Martinez-Forero I, Pelaez A, Villoslada P. Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin Pharmacother 2008;9(17):3053-67
   PubMed Web of Science ®Google Scholar
• Furlan R. Definition of non-responders: biological markers. Neurol Sci 2008;29(Suppl 2):S214-15
   Google Scholar